Stop Mapping the Journey. Find Where It Breaks.

I drive the same stretch of I-88 most mornings. Naperville, then the long corridor east, Lennon in the back seat with his head out the window, unbothered by all of it. I could draw that route from memory — every exit, every merge, the spot where the sun hits the windshield at exactly the wrong angle. 

Knowing the route has never once gotten me to work faster. 

Because the route isn’t the problem. The route is the same every day. What matters is the one morning a truck jackknifes at the Naperville Road exit and the whole thing seizes. That single point — not the forty miles I have memorized — decides whether I’m early or an hour late. The map is complete and useless. The break is everything. 

Why Does a Detailed Patient Journey Map Still Fail to Drive Adoption? 

This is what I think about when a brief asks for a patient journey. Or a treatment journey. A purchase journey, a post-prescription journey — whatever the fashionable noun. 

The team almost always already has one. A gorgeous artifact. Awareness to diagnosis to treatment to adherence, swim lanes and touchpoints and little icons, forty moments rendered in the brand’s colors. It gets admired. It practically gets laminated. And it changes nothing — because a map of forty moments tells you everything except the one thing you needed: where does this actually break, and what do we do about it? 

The scale of that adherence gap is well documented. Industry research on chronic-condition treatment shows roughly half of patients stop taking prescribed medication within the first year¹ — a break severe enough to undermine even a well-differentiated brand, and one that a standard touchpoint-by-touchpoint journey map, built and refreshed only occasionally, often isn’t structured to catch in time. 

Why Is Documenting a Journey Different From Finding Where It Breaks? 

Documenting a journey is a data exercise, and you can do it exhaustively. More touchpoints, more stages, more granularity. But the more complete the map gets, the less it tells you — because it treats all forty moments as equal, when they never are. Thirty-eight of them are decoration. Two of them are where a real human being, under real pressure, decides to keep going or drop out. 

Finding those two isn’t documentation. It’s insight. It requires knowing which moment carries the behavioral weight, why it breaks there and nowhere else, and what intervention actually changes the outcome at that exact point. 

Where Should Pharma Teams Look for the Break — and What Fixes It? 

And the intervention may sit somewhere the traditional journey map never tells you to look. It could require a change in product development, patient education, support services, or the way clinical and commercial teams understand the patient’s lived experience. 

That is why the strongest journey research doesn’t end with a map. It translates the moments that matter into aligned actions across the organization — and creates a way to revisit those moments as new evidence and new questions emerge. 

Why Do Journey Breaks Change Over Time? 

The map is the data. The break is the decision. And the equation tells you what happens with all map and no insight: a gorgeous artifact, and a funnel still leaking in precisely the place you never diagnosed. 

The breaks move, too. A new competitor, a formulary change, a shift in how patients get diagnosed, and the friction relocates. Which is why finding the break can’t be a once-every-three-years study. The road changes. So does the wreck. That’s also why speed matters here in a very literal sense: traditional patient journey development can take several weeks per therapeutic area to produce,² which is long enough for the break you’re diagnosing to have already moved. 

What Should Commercial and Medical Teams Ask For Instead of a Better Map? 

Stop asking for a better map. 

You have the map. Ask where the journey breaks, why, and what specifically changes the outcome there — and be ready to ask again when the road shifts. 

That’s what my team at Shapiro+Raj does as a life sciences insights consultancy. We don’t hand you forty moments. We hand you the two that matter, and what to do about them. 

Lennon, for the record, cares about none of this. Head out the window, every morning, the same road, purely delighted. There’s a lesson in that too. It just isn’t a commercial one.

¹ Courier Health, “Disconnected Patient Journeys: Hidden Costs to Pharma and Patients.”  

² Tellius, “The Complete Guide to Patient Journey Analytics, APLD Analysis, and LOT Analytics in Pharma.”